MIST · Milestone Pharmaceuticals Inc. · Financials
Market Cap
$98.15M
Shares
124.50M
Volume · Oct 2
161.82K
Avg daily vol (3M)
1.42M
Income-statement, balance-sheet and cash-flow figures from SEC filings, plus a debt profile anchored in the latest 10-K and updated by each 10-Q and debt exhibit.
Net Income
-$63.06M
-51.9%
FY2025
Diluted EPS
-$0.75
-11.9%
FY2025
Operating Cash Flow
-$49.04M
-70%
FY2025
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|---|
| $16.22M | $18.11M | $14.36M | $31.05M | $39.83M | $38.67M | $34.49M | $41.99M | $16.85M | |
| $16.93M | $17.27M | $16.74M | $15.93M | $15.72M | $12.4M | $10.29M | $7M | $3.05M | |
| $172K | $114K | $105K | $92K | $89K | $93K | $97K | $38K | $10K | |
| -$78.38M | -$62.14M | -$42.1M | -$61.1M | -$59.64M | -$43.07M | -$50.71M | -$57.88M | -$23.82M | |
| $10.81M | $3.84M | $3.58M | $2.55M | — | — | — | — | — | |
| $5.18M | $2.92M | $4.16M | $3.97M | — | — | — | — | — | |
| — | -$63.06M | -$41.52M | -$59.69M | -$58.39M | -$42.85M | -$49.98M | -$55.29M | -$23.11M | |
| — | — | — | — | — | — | -$17K | -$56K | $74K | |
| -$84.01M | -$63.06M | -$41.52M | -$59.69M | -$58.39M | -$42.85M | -$49.97M | -$55.23M | -$23.19M | |
| USD/shares | -$0.65 | -$0.75 | -$0.67 | -$1.39 | -$1.38 | -$1.02 | -$1.70 | — | — |
| USD/shares | -$0.65 | -$0.75 | -$0.67 | -$1.39 | -$1.38 | -$1.02 | -$1.70 | — | — |
| shares | — | — | — | — | — | — | 29.34M | 15.78M | 319.2K |
| shares | — | — | — | — | — | — | 29.34M | 15.78M | 319.2K |
Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative.
Debt Profile
Annual debt figures are established from 10-K filings and updated by subsequent 10-Q and 8-K disclosures. Instrument balances are not summed into a company total unless the filing itself reports that total.
Debt data is being processed. Please check back later.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.
Valuation
EV/Revenue
—
Peer median 4.94×
EV/EBIT
—
Peer median 12.12×
P/E (TTM)
—
Peer median 7.46×
Peer medians compare against the 310 similar-size Biotechnology companies (of 532 listed).